– Sanborn discusses study results, JAK Inhibitors, IBD trial design Positive results of a phase 2 clinical trial of upadacitinib, an oral JAK1 inhibitor, in Crohn’s disease patients were presented during the Late-Breaking Abstract Plenary Session at Digestive Disease Week 2017 in Chicago. The CELEST dose ranging study demonstrated endoscopic improvement and clinical benefit of upadacitinib …
Continue reading Upadacitinib offers hope for refractory Crohn’s disease patients in phase 2 trial